A Phase II study of TNX-102 for the treatment of agitation in Alzheimer's disease
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2018
Price : $35 *
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Agitation
- Focus Registrational; Therapeutic Use
- Sponsors Tonix Pharmaceuticals Holding Corp
- 13 Aug 2018 According to a Tonix Pharmaceuticals Holding Corp media release, the company has submitted a study protocol to FDA in July 2018 and is waiting for the review and acceptance. This would be the potential pivotal study.
- 01 May 2018 According to a Tonix Pharmaceuticals media release,t he U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) application.
- 03 Apr 2018 According to a Tonix Pharmaceuticals media release, a Phase II IND application was submitted in March 2018.